214 related articles for article (PubMed ID: 18666747)
1. Sorafenib (BAY 43-9006): review of clinical development.
Ng R; Chen EX
Curr Clin Pharmacol; 2006 Sep; 1(3):223-8. PubMed ID: 18666747
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib.
Rini BI
Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of sorafenib: clinical and molecular aspects.
Blanchet B; Billemont B; Barete S; Garrigue H; Cabanes L; Coriat R; Francès C; Knebelmann B; Goldwasser F
Expert Opin Drug Saf; 2010 Mar; 9(2):275-87. PubMed ID: 20078249
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
8. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S
Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424
[TBL] [Abstract][Full Text] [Related]
12. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
13. BAY 43-9006: early clinical data in patients with advanced solid malignancies.
Hotte SJ; Hirte HW
Curr Pharm Des; 2002; 8(25):2249-53. PubMed ID: 12369852
[TBL] [Abstract][Full Text] [Related]
14. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
15. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
[TBL] [Abstract][Full Text] [Related]
16. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in liver cancer--just the beginning.
Roberts LR
N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
[No Abstract] [Full Text] [Related]
19. Sorafenib - a small molecule with big promise?
Tadmor T; Tallman MS; Polliack A
Leuk Lymphoma; 2010 Feb; 51(2):181-2. PubMed ID: 20001865
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]